<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35658110</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2749-9642</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Medical review (2021)</Title><ISOAbbreviation>Med Rev (2021)</ISOAbbreviation></Journal><ArticleTitle>Asymptomatic and pre-symptomatic infection in Coronavirus Disease 2019 pandemic.</ArticleTitle><Pagination><StartPage>66</StartPage><EndPage>88</EndPage><MedlinePgn>66-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1515/mr-2021-0034</ELocationID><Abstract><AbstractText>With the presence of Coronavirus Disease 2019 (COVID-19) asymptomatic infections detected, their proportion, transmission potential, and other aspects such as immunity and related emerging challenges have attracted people's attention. We have found that based on high-quality research, asymptomatic infections account for at least one-third of the total cases, whereas based on systematic review and meta-analysis, the proportion is about one-fifth. Evaluating the true transmission potential of asymptomatic cases is difficult but critical, since it may affect national policies in response to COVID-19. We have summarized the current evidence and found, compared with symptomatic cases, the transmission capacity of asymptomatic individuals is weaker, even though they have similar viral load and relatively short virus shedding duration. As the outbreak progresses, asymptomatic infections have also been found to develop long COVID-19. In addition, the role of asymptomatic infection in COVID-19 remains to be further revealed as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge. Nevertheless, as asymptomatic infections transmit the SARS-CoV-2 virus silently, they still pose a substantial threat to public health. Therefore, it is essential to conduct screening to obtain more knowledge about the asymptomatic infections and to detect them as soon as possible; meanwhile, management of them is also a key point in the&#xa0;fight against COVID-19 community transmission. The different management of asymptomatic infections in various countries are compared and the experience in China is displayed in detail.</AbstractText><CopyrightInformation>&#xa9; 2022 Yutong Wang et al., published by De Gruyter, Berlin/Boston.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yutong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Ke</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-8065-7488</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Wenjing</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking University Centre for Public Health and Epidemic Preparedness and Response, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Canqing</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking University Centre for Public Health and Epidemic Preparedness and Response, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Peking University Centre for Public Health and Epidemic Preparedness and Response, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Meinian Public Health Institute, Peking University Health Science Center, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Chunxiao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking University Centre for Public Health and Epidemic Preparedness and Response, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Liming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking University Centre for Public Health and Epidemic Preparedness and Response, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Med Rev (2021)</MedlineTA><NlmUniqueID>9918383871606676</NlmUniqueID><ISSNLinking>2749-9642</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">asymptomatic</Keyword><Keyword MajorTopicYN="N">coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">pre-symptomatic</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2</Keyword></KeywordList><CoiStatement>Competing interests: Authors state no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>3</Day><Hour>14</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35658110</ArticleId><ArticleId IdType="pmc">PMC9047649</ArticleId><ArticleId IdType="doi">10.1515/mr-2021-0034</ArticleId><ArticleId IdType="pii">mr-2021-0034</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  Weekly operational update on COVID-19 &#x2013; 14 December 2021. . https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---14-december-2021 Available from:</Citation></Reference><Reference><Citation>Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann Intern Med. 2020;173:362&#x2013;7. doi: 10.7326/m20-3012.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m20-3012</ArticleId><ArticleId IdType="pmc">PMC7281624</ArticleId><ArticleId IdType="pubmed">32491919</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao W, Lv J, Pang Y, Li L. Role of asymptomatic and pre-symptomatic infections in Covid-19 pandemic. BMJ. 2021;375:n2342. doi: 10.1136/bmj.n2342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2342</ArticleId><ArticleId IdType="pmc">PMC8634419</ArticleId><ArticleId IdType="pubmed">34852994</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuya-Kanamori L, Cox M, Milinovich GJ, Magalhaes RJ, Mackay IM, Yakob L. Heterogeneous and dynamic prevalence of asymptomatic influenza virus infections. Emerg Infect Dis. 2016;22:1052&#x2013;6. doi: 10.3201/eid2206.151080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2206.151080</ArticleId><ArticleId IdType="pmc">PMC4880086</ArticleId><ArticleId IdType="pubmed">27191967</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsueh PR, Kao CL, Lee CN, Chen LK, Ho MS, Sia C, et al. SARS antibody test for serosurveillance. Emerg Infect Dis. 2004;10:1558&#x2013;62. doi: 10.3201/eid1009.040101.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1009.040101</ArticleId><ArticleId IdType="pmc">PMC3320307</ArticleId><ArticleId IdType="pubmed">15498156</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  . Middle East respiratory syndrome coronavirus (MERS-CoV) WHO MERS global summary and assessment of risk. 2018. https://www.who.int/csr/disease/coronavirus_infections/risk-assessment-august-2018.pdf?ua=1&amp;ua=1&amp;ua=1 WHO.</Citation></Reference><Reference><Citation>WHO  . Middle East respiratory syndrome coronavirus (MERS-CoV) WHO MERS global summary and assessment of risk. 2018. https://apps.who.int/iris/bitstream/handle/10665/326126/WHO-MERS-RA-19.1-eng.pdf WHO.</Citation></Reference><Reference><Citation>Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan. Euro Surveill. 2020;2020:25. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.10.2000180</ArticleId><ArticleId IdType="pmc">PMC7078829</ArticleId><ArticleId IdType="pubmed">32183930</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19) Int J Infect Dis. 2020;94:154&#x2013;5. doi: 10.1016/j.ijid.2020.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.03.020</ArticleId><ArticleId IdType="pmc">PMC7270890</ArticleId><ArticleId IdType="pubmed">32179137</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneghan C, Brassey J, Jefferson T.  COVID-19: what proportion are asymptomatic? Oxford: Centre for Evidence Based Medicine; 2020. https://www.cebm.net/covid-19/covid-19-what-proportion-are-asymptomatic/ Available from:</Citation></Reference><Reference><Citation>Al-Sadeq DW, Nasrallah GK. The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review. Int J Infect Dis. 2020;98:372&#x2013;80. doi: 10.1016/j.ijid.2020.06.098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.06.098</ArticleId><ArticleId IdType="pmc">PMC7330573</ArticleId><ArticleId IdType="pubmed">32623083</ArticleId></ArticleIdList></Reference><Reference><Citation>Syangtan G, Bista S, Dawadi P, Rayamajhee B, Shrestha LB, Tuladhar R, et al. Asymptomatic SARS-CoV-2 carriers: a systematic review and meta-analysis. Front Public Health. 2020;8:587374. doi: 10.3389/fpubh.2020.587374.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.587374</ArticleId><ArticleId IdType="pmc">PMC7855302</ArticleId><ArticleId IdType="pubmed">33553089</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Zhu C, Yan D, Liu H, Li D, Zhou Y, et al. The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): a systematic review and meta-analysis. Int J Infect Dis. 2021;104:458&#x2013;64. doi: 10.1016/j.ijid.2021.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.01.017</ArticleId><ArticleId IdType="pmc">PMC7833455</ArticleId><ArticleId IdType="pubmed">33444755</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Guo Y, Mao R, Zhang J. Proportion of asymptomatic coronavirus disease 2019: a systematic review and meta-analysis. J Med Virol. 2021;93:820&#x2013;30. doi: 10.1002/jmv.26326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26326</ArticleId><ArticleId IdType="pmc">PMC7404334</ArticleId><ArticleId IdType="pubmed">32691881</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al. Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Proc Natl Acad Sci USA. 2021;118:e2109229118. doi: 10.1073/pnas.2109229118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2109229118</ArticleId><ArticleId IdType="pmc">PMC8403749</ArticleId><ArticleId IdType="pubmed">34376550</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren O, Cardona M, Bell K, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. JAMMI. 2020;5:223&#x2013;4. doi: 10.3138/jammi-2020-0030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3138/jammi-2020-0030</ArticleId><ArticleId IdType="pmc">PMC9602871</ArticleId><ArticleId IdType="pubmed">36340059</ArticleId></ArticleIdList></Reference><Reference><Citation>Beale S, Hayward A, Shallcross L, Aldridge R, Fragaszy E. A rapid review and meta-analysis of the asymptomatic proportion of PCR-confirmed SARS-CoV-2 infections in community settings [version 1; peer review: 1 approved with reservations] Wellcome Open Res. 2020;5:266. doi: 10.12688/wellcomeopenres.16387.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.16387.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med. 2020;17:e1003346. doi: 10.1371/journal.pmed.1003346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003346</ArticleId><ArticleId IdType="pmc">PMC7508369</ArticleId><ArticleId IdType="pubmed">32960881</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Asymptomatic SARS coronavirus 2 infection: invisible yet invincible. Int J Infect Dis. 2020;100:112&#x2013;6. doi: 10.1016/j.ijid.2020.08.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.08.076</ArticleId><ArticleId IdType="pmc">PMC7470698</ArticleId><ArticleId IdType="pubmed">32891737</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, et al. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: a systematic review and meta-analysis. PLoS One. 2020;15:e0241536. doi: 10.1371/journal.pone.0241536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0241536</ArticleId><ArticleId IdType="pmc">PMC7608887</ArticleId><ArticleId IdType="pubmed">33141862</ArticleId></ArticleIdList></Reference><Reference><Citation>Oran DP, Topol EJ. The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review. Ann Intern Med. 2021;174:655&#x2013;62. doi: 10.7326/m20-6976.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m20-6976</ArticleId><ArticleId IdType="pmc">PMC7839426</ArticleId><ArticleId IdType="pubmed">33481642</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e2137257. doi: 10.1001/jamanetworkopen.2021.37257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.37257</ArticleId><ArticleId IdType="pmc">PMC8672238</ArticleId><ArticleId IdType="pubmed">34905008</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SY, Kim YM, Yi S, Lee S, Na BJ, Kim CB, et al. Coronavirus disease outbreak in call center, South Korea. Emerg Infect Dis. 2020;26:1666&#x2013;70. doi: 10.3201/eid2608.201274.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.201274</ArticleId><ArticleId IdType="pmc">PMC7392450</ArticleId><ArticleId IdType="pubmed">32324530</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo&#x2019;. Nature. 2020;584:425&#x2013;9. doi: 10.1038/s41586-020-2488-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2488-1</ArticleId><ArticleId IdType="pubmed">32604404</ArticleId></ArticleIdList></Reference><Reference><Citation>Roxby AC, Greninger AL, Hatfield KM, Lynch JB, Dellit TH, James A, et al. Detection of SARS-CoV-2 among residents and staff members of an independent and assisted living community for older adults - Seattle, Washington, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:416&#x2013;8. doi: 10.15585/mmwr.mm6914e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6914e2</ArticleId><ArticleId IdType="pmc">PMC7147909</ArticleId><ArticleId IdType="pubmed">32271726</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadi N, Wu SC, Spihlman AP, Moulton VR. What&#x2019;s sex got to do with COVID-19? Gender-based differences in the host immune response to coronaviruses. Front Immunol. 2020;11:2147. doi: 10.3389/fimmu.2020.02147.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.02147</ArticleId><ArticleId IdType="pmc">PMC7485092</ArticleId><ArticleId IdType="pubmed">32983176</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang R, Gui X, Xiong Y. Comparison of clinical characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China. JAMA Netw Open. 2020;3:e2010182. doi: 10.1001/jamanetworkopen.2020.10182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.10182</ArticleId><ArticleId IdType="pmc">PMC7254178</ArticleId><ArticleId IdType="pubmed">32459353</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;80 e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;202:756&#x2013;9. doi: 10.1164/rccm.202001-0179le.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202001-0179le</ArticleId><ArticleId IdType="pmc">PMC7462411</ArticleId><ArticleId IdType="pubmed">32663409</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciaglia E, Vecchione C, Puca AA. COVID-19 infection and circulating ACE2 levels: protective role in women and children. Front Pediatr. 2020;8:206. doi: 10.3389/fped.2020.00206.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2020.00206</ArticleId><ArticleId IdType="pmc">PMC7192005</ArticleId><ArticleId IdType="pubmed">32391299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wambier CG, Goren A, Vano-Galvan S, Ramos PM, Ossimetha A, Nau G, et al. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. 2020;81:771&#x2013;6. doi: 10.1002/ddr.21688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.21688</ArticleId><ArticleId IdType="pmc">PMC7273095</ArticleId><ArticleId IdType="pubmed">32412125</ArticleId></ArticleIdList></Reference><Reference><Citation>Younes N, Al-Sadeq DW, Al-Jighefee H, Younes S, Al-Jamal O, Daas HI, et al. Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2. Viruses. 2020;12:582. doi: 10.3390/v12060582.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12060582</ArticleId><ArticleId IdType="pmc">PMC7354519</ArticleId><ArticleId IdType="pubmed">32466458</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WL, Zou N, Guan WH, Pan JL, Xu W. Clinical characteristics of COVID-19 in family clusters: a systematic review. World J Pediatr. 2021;17:355&#x2013;63. doi: 10.1007/s12519-021-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-021-00434-z</ArticleId><ArticleId IdType="pmc">PMC8229253</ArticleId><ArticleId IdType="pubmed">34170503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz AT, Zeichner SL. COVID-19 in children: initial characterization of the pediatric disease. Pediatrics. 2020;145:e20200834. doi: 10.1542/peds.2020-0834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2020-0834</ArticleId><ArticleId IdType="pubmed">32179659</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020;382:2302&#x2013;15. doi: 10.1056/nejmoa2006100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2006100</ArticleId><ArticleId IdType="pmc">PMC7175425</ArticleId><ArticleId IdType="pubmed">32289214</ArticleId></ArticleIdList></Reference><Reference><Citation>Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P, Del Campo R, Ciapponi A, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. PLoS One. 2020;15:e0242958. doi: 10.1371/journal.pone.0242958.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0242958</ArticleId><ArticleId IdType="pmc">PMC7728293</ArticleId><ArticleId IdType="pubmed">33301459</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) Clin Infect Dis. 2020;71:778&#x2013;85. doi: 10.1093/cid/ciaa310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa310</ArticleId><ArticleId IdType="pmc">PMC7184472</ArticleId><ArticleId IdType="pubmed">32198501</ArticleId></ArticleIdList></Reference><Reference><Citation>Petherick A. Developing antibody tests for SARS-CoV-2. Lancet. 2020;395:1101&#x2013;2. doi: 10.1016/s0140-6736(20)30788-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30788-1</ArticleId><ArticleId IdType="pmc">PMC7270070</ArticleId><ArticleId IdType="pubmed">32247384</ArticleId></ArticleIdList></Reference><Reference><Citation>Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J Clin Virol. 2020;128:104437. doi: 10.1016/j.jcv.2020.104437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104437</ArticleId><ArticleId IdType="pmc">PMC7219425</ArticleId><ArticleId IdType="pubmed">32434708</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Q, Hu Y, Peng B, Tang X-J, Wang W, Su K, et al. Effective control of SARS-CoV-2 transmission in Wanzhou, China. Nat Med. 2021;27:86&#x2013;93. doi: 10.1038/s41591-020-01178-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01178-5</ArticleId><ArticleId IdType="pubmed">33257893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward H, Cooke G, Atchison C, Whitaker M, Elliott J, Moshe M, et al. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. Lancet Reg Health Eur. 2021;4:100098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8088780</ArticleId><ArticleId IdType="pubmed">33969335</ArticleId></ArticleIdList></Reference><Reference><Citation>Poll&#xe1;n M, P&#xe9;rez-G&#xf3;mez B, Pastor-Barriuso R, Oteo J, Hern&#xe1;n MA, P&#xe9;rez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396:535&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7336131</ArticleId><ArticleId IdType="pubmed">32645347</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, et al. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA. 2020;323:1915&#x2013;23. doi: 10.1001/jama.2020.6130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6130</ArticleId><ArticleId IdType="pmc">PMC7149375</ArticleId><ArticleId IdType="pubmed">32275295</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao X, Cheng S, Wu D, Wu T, Lin X, Wang C. Reconstruction of the full transmission dynamics of COVID-19 in Wuhan. Nature. 2020;584:420&#x2013;4. doi: 10.1038/s41586-020-2554-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2554-8</ArticleId><ArticleId IdType="pubmed">32674112</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayorga L, Garc&#xed;a Samartino C, Flores G, Masuelli S, S&#xe1;nchez MV, Mayorga LS, et al. A modelling study highlights the power of detecting and isolating asymptomatic or very mildly affected individuals for COVID-19 epidemic management. BMC Publ Health. 2020;20:1809. doi: 10.1186/s12889-020-09843-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-09843-7</ArticleId><ArticleId IdType="pmc">PMC7691976</ArticleId><ArticleId IdType="pubmed">33246432</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2) Science. 2020;368:489&#x2013;93. doi: 10.1126/science.abb3221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3221</ArticleId><ArticleId IdType="pmc">PMC7164387</ArticleId><ArticleId IdType="pubmed">32179701</ArticleId></ArticleIdList></Reference><Reference><Citation>Ing AJ, Cocks C, Green JP. COVID-19: in the footsteps of Ernest Shackleton. Thorax. 2020;75:693&#x2013;4. doi: 10.1136/thoraxjnl-2020-215091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215091</ArticleId><ArticleId IdType="pmc">PMC7402559</ArticleId><ArticleId IdType="pubmed">32461231</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Harrich D, Li Z, Hu D, Li D. The unique features of SARS-CoV-2 transmission: comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus. Rev Med Virol. 2021;31:e2171. doi: 10.1002/rmv.2171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2171</ArticleId><ArticleId IdType="pmc">PMC7537046</ArticleId><ArticleId IdType="pubmed">33350025</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323:1406&#x2013;7. doi: 10.1001/jama.2020.2565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2565</ArticleId><ArticleId IdType="pmc">PMC7042844</ArticleId><ArticleId IdType="pubmed">32083643</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020;63:706&#x2013;11. doi: 10.1007/s11427-020-1661-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-020-1661-4</ArticleId><ArticleId IdType="pmc">PMC7088568</ArticleId><ArticleId IdType="pubmed">32146694</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Su YY, Zhi SS, Huang J, Zhuang CL, Bai WZ, et al. Virus shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2. Clin Microbiol Infect. 2020;26:1556 e1&#x2013;e6. doi: 10.1016/j.cmi.2020.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.008</ArticleId><ArticleId IdType="pmc">PMC7346822</ArticleId><ArticleId IdType="pubmed">32653662</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilmes P, Zimmer J, Schulz J, Glod F, Veiber L, Mombaerts L, et al. SARS-CoV-2 transmission risk from asymptomatic carriers: results from a mass screening programme in Luxembourg. Lancet Reg Health Eur. 2021;4:100056. doi: 10.1016/j.lanepe.2021.100056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100056</ArticleId><ArticleId IdType="pmc">PMC7912359</ArticleId><ArticleId IdType="pubmed">33997830</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M, Yang L, Chen X, Deng Y, Yang S, Xu H, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. Respir Med. 2020;169:106026. doi: 10.1016/j.rmed.2020.106026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2020.106026</ArticleId><ArticleId IdType="pmc">PMC7219423</ArticleId><ArticleId IdType="pubmed">32513410</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffle AE, Gill M. Mass screening for asymptomatic SARS-CoV-2 infection. BMJ. 2021;373:n1058. doi: 10.1136/bmj.n1058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1058</ArticleId><ArticleId IdType="pubmed">33910784</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung NHL. Transmissibility and transmission of respiratory viruses. Nat Rev Microbiol. 2021;19:528&#x2013;45. doi: 10.1038/s41579-021-00535-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00535-6</ArticleId><ArticleId IdType="pmc">PMC7982882</ArticleId><ArticleId IdType="pubmed">33753932</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng OT, Marimuthu K, Koh V, Pang J, Linn KZ, Sun J, et al. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study. Lancet Infect Dis. 2021;21:333&#x2013;43. doi: 10.1016/s1473-3099(20)30833-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(20)30833-1</ArticleId><ArticleId IdType="pmc">PMC7831879</ArticleId><ArticleId IdType="pubmed">33152271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microb. 2021;2:e13&#x2013;22. doi: 10.1016/s2666-5247(20)30172-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2666-5247(20)30172-5</ArticleId><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee C, Kanjilal S, Baker M, Klompas M. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? Clin Infect Dis. 2021;72:1467&#x2013;74. doi: 10.1093/cid/ciaa1249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1249</ArticleId><ArticleId IdType="pmc">PMC7499497</ArticleId><ArticleId IdType="pubmed">33029620</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom MR, Mina MJ. To interpret the SARS-CoV-2 test, consider the cycle threshold value. Clin Infect Dis. 2020;71:2252&#x2013;4. doi: 10.1093/cid/ciaa619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa619</ArticleId><ArticleId IdType="pmc">PMC7314112</ArticleId><ArticleId IdType="pubmed">32435816</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock AM, Lancaster J. Asymptomatic transmission of Covid-19. BMJ. 2020;371:m4851. doi: 10.1136/bmj.m4851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4851</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf6;lfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, M&#xfc;ller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465&#x2013;9. doi: 10.1038/s41586-020-2196-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382:2081&#x2013;90. doi: 10.1056/nejmoa2008457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2008457</ArticleId><ArticleId IdType="pmc">PMC7200056</ArticleId><ArticleId IdType="pubmed">32329971</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJ, Brookes AJ, Pollock AM. Operation moonshot proposals are scientifically unsound. BMJ. 2020;370:m3699. doi: 10.1136/bmj.m3699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3699</ArticleId><ArticleId IdType="pubmed">32963111</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections - the state of the art. Emerg Microb Infect. 2020;9:747&#x2013;56. doi: 10.1080/22221751.2020.1745095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1745095</ArticleId><ArticleId IdType="pmc">PMC7172701</ArticleId><ArticleId IdType="pubmed">32196430</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25:2000045. doi: 10.2807/1560-7917.ES.2020.25.3.2000045.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.3.2000045</ArticleId><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020;39:1059&#x2013;61. doi: 10.1007/s10096-020-03913-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-020-03913-9</ArticleId><ArticleId IdType="pmc">PMC7185831</ArticleId><ArticleId IdType="pubmed">32342252</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for coronavirus disease 2019 infectivity assessment: a systematic review. Clin Infect Dis. 2021;73:e3884&#x2013;99. doi: 10.1093/cid/ciaa1764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1764</ArticleId><ArticleId IdType="pmc">PMC7799320</ArticleId><ArticleId IdType="pubmed">33270107</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R, Li F, Chen F, Liu H, Zheng J, Lei C, et al. Viral dynamics in asymptomatic patients with COVID-19. Int J Infect Dis. 2020;96:288&#x2013;90. doi: 10.1016/j.ijid.2020.05.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.05.030</ArticleId><ArticleId IdType="pmc">PMC7211726</ArticleId><ArticleId IdType="pubmed">32437933</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Li P, Ding Y, Liu M, Liu L, Yi B, et al. Epidemiological feature, viral shedding, and antibody seroconversion among asymptomatic SARS-CoV-2 carriers and symptomatic/presymptomatic COVID-19 patients. J Infect Publ Health. 2021;14:845&#x2013;51. doi: 10.1016/j.jiph.2021.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2021.05.003</ArticleId><ArticleId IdType="pmc">PMC8154191</ArticleId><ArticleId IdType="pubmed">34118734</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwierzeck V, K&#xf6;nig JC, K&#xfc;hn J, Mellmann A, Correa-Mart&#xed;nez CL, Omran H, et al. First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 in a pediatric dialysis unit. Clin Infect Dis. 2021;72:265&#x2013;70. doi: 10.1093/cid/ciaa491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa491</ArticleId><ArticleId IdType="pmc">PMC7197625</ArticleId><ArticleId IdType="pubmed">33501962</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. Elife. 2020;9:e58728. doi: 10.7554/eLife.58728.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.58728</ArticleId><ArticleId IdType="pmc">PMC7314537</ArticleId><ArticleId IdType="pubmed">32392129</ArticleId></ArticleIdList></Reference><Reference><Citation>Han MS, Seong MW, Kim N, Shin S, Cho SI, Park H, et al. Viral RNA load in mildly symptomatic and asymptomatic children with COVID-19, Seoul, South Korea. Emerg Infect Dis. 2020;26:2497&#x2013;9. doi: 10.3201/eid2610.202449.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2610.202449</ArticleId><ArticleId IdType="pmc">PMC7510743</ArticleId><ArticleId IdType="pubmed">32497001</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao T, Wang Y, Yuan J, Ye H, Wei L, Liao X, et al. Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers. Front Med. 2021;8:595773. doi: 10.3389/fmed.2021.595773.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.595773</ArticleId><ArticleId IdType="pmc">PMC8005564</ArticleId><ArticleId IdType="pubmed">33791320</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Vinh Chau N, Lam VT, Dung NT, Yen LM, Minh NNQ, Hung LM, et al. The natural history and transmission potential of asymptomatic severe acute respiratory syndrome coronavirus 2 infection. Clin Infect Dis. 2020;71:2679&#x2013;87. doi: 10.1093/cid/ciaa711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa711</ArticleId><ArticleId IdType="pmc">PMC7314145</ArticleId><ArticleId IdType="pubmed">32497212</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorzalski AJ, Hartley P, Laverdure C, Kerwin H, Tillett R, Verma S, et al. Characteristics of viral specimens collected from asymptomatic and fatal cases of COVID-19. J Biomed Res. 2020;34:431&#x2013;6. doi: 10.7555/jbr.34.20200110.</Citation><ArticleIdList><ArticleId IdType="doi">10.7555/jbr.34.20200110</ArticleId><ArticleId IdType="pmc">PMC7718074</ArticleId><ArticleId IdType="pubmed">33243941</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177&#x2013;9. doi: 10.1056/nejmc2001737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmc2001737</ArticleId><ArticleId IdType="pmc">PMC7121626</ArticleId><ArticleId IdType="pubmed">32074444</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. 2020;180:1156&#x2013;63. doi: 10.1001/jamainternmed.2020.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.2020</ArticleId><ArticleId IdType="pmc">PMC7195694</ArticleId><ArticleId IdType="pubmed">32356867</ArticleId></ArticleIdList></Reference><Reference><Citation>Huff HV, Singh A. Asymptomatic transmission during the coronavirus disease 2019 pandemic and implications for public health strategies. Clin Infect Dis. 2020;71:2752&#x2013;6. doi: 10.1093/cid/ciaa654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa654</ArticleId><ArticleId IdType="pmc">PMC7314132</ArticleId><ArticleId IdType="pubmed">32463076</ArticleId></ArticleIdList></Reference><Reference><Citation>Ra SH, Lim JS, Kim GU, Kim MJ, Jung J, Kim SH. Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection. Thorax. 2021;76:61&#x2013;3. doi: 10.1136/thoraxjnl-2020-215042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215042</ArticleId><ArticleId IdType="pubmed">32963115</ArticleId></ArticleIdList></Reference><Reference><Citation>Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. 2020;25:2001483. doi: 10.2807/1560-7917.ES.2020.25.32.2001483.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.32.2001483</ArticleId><ArticleId IdType="pmc">PMC7427302</ArticleId><ArticleId IdType="pubmed">32794447</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyton RJ, Altmann DM. The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions? Nat Rev Immunol. 2021;21:762&#x2013;68. doi: 10.1038/s41577-021-00631-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00631-x</ArticleId><ArticleId IdType="pmc">PMC8525456</ArticleId><ArticleId IdType="pubmed">34667307</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones TC, Biele G, Muhlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, et al. Estimating infectiousness throughout SARS-CoV-2 infection course. Science. 2021;373:eabi5273. doi: 10.1126/science.abi5273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abi5273</ArticleId><ArticleId IdType="pmc">PMC9267347</ArticleId><ArticleId IdType="pubmed">34035154</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Wu X, Zhou H, Xu F. Clinical characteristics and infectivity of asymptomatic carriers of SARS-CoV-2 (review) Exp Ther Med. 2021;21:115. doi: 10.3892/etm.2020.9547.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2020.9547</ArticleId><ArticleId IdType="pmc">PMC7739853</ArticleId><ArticleId IdType="pubmed">33335578</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26:672&#x2013;5. doi: 10.1038/s41591-020-0869-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0869-5</ArticleId><ArticleId IdType="pubmed">32296168</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. JAMA Intern Med. 2020;180:1447&#x2013;52. doi: 10.1001/jamainternmed.2020.3862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3862</ArticleId><ArticleId IdType="pmc">PMC7411944</ArticleId><ArticleId IdType="pubmed">32780793</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa NW, Brooks JT, Sobel J. Evidence supporting transmission of severe acute respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic. Emerg Infect Dis. 2020;26:e201595. doi: 10.3201/eid2607.201595.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2607.201595</ArticleId><ArticleId IdType="pmc">PMC7323549</ArticleId><ArticleId IdType="pubmed">32364890</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogrady B. What the data say about asymptomatic COVID infections. Nature. 2020;587:534&#x2013;5. doi: 10.1038/d41586-020-03141-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-03141-3</ArticleId><ArticleId IdType="pubmed">33214725</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J Infect. 2020;81:357&#x2013;71. doi: 10.1016/j.jinf.2020.06.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.06.067</ArticleId><ArticleId IdType="pmc">PMC7323671</ArticleId><ArticleId IdType="pubmed">32615199</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen AL, Popescu SV. SARS-CoV-2 transmission without symptoms. Science. 2021;371:1206&#x2013;7. doi: 10.1126/science.abf9569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf9569</ArticleId><ArticleId IdType="pubmed">33737476</ArticleId></ArticleIdList></Reference><Reference><Citation>Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200&#x2013;4. doi: 10.1038/s41591-020-0965-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0965-6</ArticleId><ArticleId IdType="pubmed">32555424</ArticleId></ArticleIdList></Reference><Reference><Citation>Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, et al. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerg Microb Infect. 2020;9:833&#x2013;6. doi: 10.1080/22221751.2020.1756699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1756699</ArticleId><ArticleId IdType="pmc">PMC7241531</ArticleId><ArticleId IdType="pubmed">32306864</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontana LM, Villamagna AH, Sikka MK, McGregor JC. Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): review of current literature. Infect Control Hosp Epidemiol. 2021;42:659&#x2013;68. doi: 10.1017/ice.2020.1273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ice.2020.1273</ArticleId><ArticleId IdType="pmc">PMC7691645</ArticleId><ArticleId IdType="pubmed">33077007</ArticleId></ArticleIdList></Reference><Reference><Citation>Widders A, Broom A, Broom J. SARS-CoV-2: the viral shedding vs infectivity dilemma. Infect Dis Health. 2020;25:210&#x2013;5. doi: 10.1016/j.idh.2020.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idh.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC7237903</ArticleId><ArticleId IdType="pubmed">32473952</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kampen JJA, van de Vijver D, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) Nat Commun. 2021;12:267. doi: 10.1038/s41467-020-20568-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20568-4</ArticleId><ArticleId IdType="pmc">PMC7801729</ArticleId><ArticleId IdType="pubmed">33431879</ArticleId></ArticleIdList></Reference><Reference><Citation>Masia M, Telenti G, Fernandez M, Garcia JA, Agullo V, Padilla S, et al. SARS-CoV-2 seroconversion and viral clearance in patients hospitalized with COVID-19: viral load predicts antibody response. Open Forum Infect Dis. 2021;8:ofab005. doi: 10.1093/ofid/ofab005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab005</ArticleId><ArticleId IdType="pmc">PMC7881755</ArticleId><ArticleId IdType="pubmed">33614814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayampanathan AA, Heng CS, Pin PH, Pang J, Leong TY, Lee VJ. Infectivity of asymptomatic versus symptomatic COVID-19. Lancet. 2021;397:93&#x2013;4. doi: 10.1016/s0140-6736(20)32651-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)32651-9</ArticleId><ArticleId IdType="pmc">PMC7836843</ArticleId><ArticleId IdType="pubmed">33347812</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WD, Chang SY, Wang JT, Tsai MJ, Hung CC, Hsu CL, et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19. J Infect. 2020;81:318&#x2013;56. doi: 10.1016/j.jinf.2020.03.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.063</ArticleId><ArticleId IdType="pmc">PMC7151379</ArticleId><ArticleId IdType="pubmed">32283147</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z, Ren L, Yang J, Guo L, Feng L, Ma C, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet. 2021;397:1075&#x2013;84. doi: 10.1016/s0140-6736(21)00238-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00238-5</ArticleId><ArticleId IdType="pmc">PMC7972311</ArticleId><ArticleId IdType="pubmed">33743869</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Guan X, Mao N, Luo H, Qin Y, He N, et al. Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China. Lancet Reg Health West Pac. 2021;8:100094. doi: 10.1016/j.lanwpc.2021.100094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2021.100094</ArticleId><ArticleId IdType="pmc">PMC7864613</ArticleId><ArticleId IdType="pubmed">33585828</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu X, Nergiz AI, Maraolo AE, Bogoch II, Low N, Cevik M. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission-a living systematic review. Clin Microbiol Infect. 2021;27:511&#x2013;9. doi: 10.1016/j.cmi.2021.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.01.011</ArticleId><ArticleId IdType="pmc">PMC7825872</ArticleId><ArticleId IdType="pubmed">33484843</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862. doi: 10.1136/bmj.m3862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3862</ArticleId><ArticleId IdType="pubmed">33097561</ArticleId></ArticleIdList></Reference><Reference><Citation>Armitage P, Colton T. Encyclopedia of biostatistics || secondary attack rate. New York City, United States: John Wiley &amp; Sons, Ltd; 2005.</Citation></Reference><Reference><Citation>Koh WC, Naing L, Chaw L, Rosledzana MA, Alikhan MF, Jamaludin SA, et al. What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors. PLoS One. 2020;15:e0240205. doi: 10.1371/journal.pone.0240205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240205</ArticleId><ArticleId IdType="pmc">PMC7544065</ArticleId><ArticleId IdType="pubmed">33031427</ArticleId></ArticleIdList></Reference><Reference><Citation>Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. JAMA Netw Open. 2020;3:e2031756. doi: 10.1001/jamanetworkopen.2020.31756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.31756</ArticleId><ArticleId IdType="pmc">PMC7737089</ArticleId><ArticleId IdType="pubmed">33315116</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, Liu F, Chang Z, Lin Y, Ren M, Zheng C, et al. Assessing asymptomatic, pre-symptomatic and symptomatic transmission risk of SARS-CoV-2. Clin Infect Dis. 2021;73:e1314&#x2013;20. doi: 10.1093/cid/ciab271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab271</ArticleId><ArticleId IdType="pmc">PMC8083716</ArticleId><ArticleId IdType="pubmed">33772573</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi Q, Lessler JA-O, Eckerle I, Lauer SA, Kaiser L, Vuilleumier N, et al. Insights into household transmission of SARS-CoV-2 from a population-based serological survey. Nat Commun. 2021;12:3643. doi: 10.1038/s41467-021-23733-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23733-5</ArticleId><ArticleId IdType="pmc">PMC8206123</ArticleId><ArticleId IdType="pubmed">34131124</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen F, Fu D, Yang Q, Geng Z, Xia J, Wang Z, et al. Low transmission risk of 9 asymptomatic carriers tested positive for both SARS-CoV-2 nucleic acid and serum IgG. J Infect. 2020;81:452&#x2013;82. doi: 10.1016/j.jinf.2020.06.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.06.034</ArticleId><ArticleId IdType="pmc">PMC7299860</ArticleId><ArticleId IdType="pubmed">32562791</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Wang AH, Yi B, Ding KQ, Wang HB, Wang JM, et al. Epidemiological characteristics of infection in COVID-19 close contacts in Ningbo city. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41:667&#x2013;71. doi: 10.3760/cma.j.cn112338-20200304-00251.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112338-20200304-00251</ArticleId><ArticleId IdType="pubmed">32447904</ArticleId></ArticleIdList></Reference><Reference><Citation>He D, Zhao S, Lin Q, Zhuang Z, Cao P, Wang MH, et al. The relative transmissibility of asymptomatic COVID-19 infections among close contacts. Int J Infect Dis. 2020;94:145&#x2013;7. doi: 10.1016/j.ijid.2020.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.04.034</ArticleId><ArticleId IdType="pmc">PMC7166025</ArticleId><ArticleId IdType="pubmed">32315808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-D&#xf6;rner L, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science. 2020;368 doi: 10.1126/science.abb6936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb6936</ArticleId><ArticleId IdType="pmc">PMC7164555</ArticleId><ArticleId IdType="pubmed">32234805</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajo K, Nishiura H. Exploring secondary SARS-CoV-2 transmission from asymptomatic cases using contact tracing data. Theor Biol Med Model. 2021;18:12. doi: 10.1186/s12976-021-00144-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12976-021-00144-z</ArticleId><ArticleId IdType="pmc">PMC8284042</ArticleId><ArticleId IdType="pubmed">34271962</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Zhu Y, Qi C, Liu L, Zhang D, Wang X, et al. Estimating the prevalence of asymptomatic COVID-19 cases and their contribution in transmission - using Henan Province, China, as an example. Front Med. 2021;8:591372. doi: 10.3389/fmed.2021.591372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.591372</ArticleId><ArticleId IdType="pmc">PMC8260942</ArticleId><ArticleId IdType="pubmed">34249953</ArticleId></ArticleIdList></Reference><Reference><Citation>McAloon C, Collins A, Hunt K, Barber A, Byrne AW, Butler F, et al. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. BMJ Open. 2020;10:e039652. doi: 10.1136/bmjopen-2020-039652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-039652</ArticleId><ArticleId IdType="pmc">PMC7430485</ArticleId><ArticleId IdType="pubmed">32801208</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 2021;4:e2035057. doi: 10.1001/jamanetworkopen.2020.35057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.35057</ArticleId><ArticleId IdType="pmc">PMC7791354</ArticleId><ArticleId IdType="pubmed">33410879</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W. Estimating the presymptomatic transmission of COVID19 using incubation period and serial interval data. medRxiv. 2020 doi: 10.1101/2020.04.02.20051318. [preprint]</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.02.20051318</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Liu D, Liao X-L, Wu X-B, Jing Q-L, Zheng J-Z, et al. Modes of contact and risk of transmission in COVID-19 among close contacts. medRxiv. 2020 doi: 10.1101/2020.03.24.20042606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.24.20042606</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaw L, Koh WC, Jamaludin SA, Naing L, Alikhan MF, Wong J. Analysis of SARS-CoV-2 transmission in different settings, Brunei. Emerg Infect Dis. 2020;26:2598. doi: 10.3201/eid2611.202263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2611.202263</ArticleId><ArticleId IdType="pmc">PMC7588541</ArticleId><ArticleId IdType="pubmed">33035448</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Cheng W, Luo L, Ma Y, Xu C, Qin P, et al. Secondary transmission of coronavirus disease from presymptomatic persons, China. Emerg Infect Dis. 2020;26:1924&#x2013;6. doi: 10.3201/eid2608.201142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.201142</ArticleId><ArticleId IdType="pmc">PMC7392433</ArticleId><ArticleId IdType="pubmed">32453686</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao S, Gan Y, Wang C, Bachmann M, Wei S, Gong J, et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Nat Commun. 2020;11:5917. doi: 10.1038/s41467-020-19802-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19802-w</ArticleId><ArticleId IdType="pmc">PMC7679396</ArticleId><ArticleId IdType="pubmed">33219229</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles&#x2019; heel of current strategies to control Covid-19. N Engl J Med. 2020;382:2158&#x2013;60. doi: 10.1056/nejme2009758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejme2009758</ArticleId><ArticleId IdType="pmc">PMC7200054</ArticleId><ArticleId IdType="pubmed">32329972</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Chen Q, Feng L, Rodewald L, Xia Y, Yu H, et al. Active case finding with case management: the key to tackling the COVID-19 pandemic. Lancet. 2020;396:63&#x2013;70. doi: 10.1016/s0140-6736(20)31278-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)31278-2</ArticleId><ArticleId IdType="pmc">PMC7272157</ArticleId><ArticleId IdType="pubmed">32505220</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebell MH, Chupp C, Bentivegna M. A high proportion of SARS-CoV-2-infected university students are asymptomatic. J Fam Pract. 2020;69:428&#x2013;9. doi: 10.12788/jfp.0102.</Citation><ArticleIdList><ArticleId IdType="doi">10.12788/jfp.0102</ArticleId><ArticleId IdType="pubmed">33176345</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, Zhang S, Lu S, Yang J, Cheng Y, Liu Y, et al. All five COVID-19 outbreaks during epidemic period of 2020/2021 in China were instigated by asymptomatic or pre-symptomatic individuals. J Biosaf Biosecur. 2021;3:35&#x2013;40. doi: 10.1016/j.jobb.2021.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jobb.2021.04.001</ArticleId><ArticleId IdType="pmc">PMC8139231</ArticleId><ArticleId IdType="pubmed">34060545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172:577&#x2013;82. doi: 10.7326/m20-0504.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m20-0504</ArticleId><ArticleId IdType="pmc">PMC7081172</ArticleId><ArticleId IdType="pubmed">32150748</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevention CfDCa  Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) . 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html Available from: [Updated 16 Feb 2021]</Citation></Reference><Reference><Citation>Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996&#x2013;1012 e19. doi: 10.1016/j.cell.2020.09.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.038</ArticleId><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183:158&#x2013;68 e14. doi: 10.1016/j.cell.2020.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones NK, Rivett L, Seaman S, Samworth RJ, Warne B, Workman C, et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. Elife. 2021;10:e68808. doi: 10.7554/elife.68808.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/elife.68808</ArticleId><ArticleId IdType="pmc">PMC8064747</ArticleId><ArticleId IdType="pubmed">33830018</ArticleId></ArticleIdList></Reference><Reference><Citation>Tande AJ, Pollock BD, Shah ND, Farrugia G, Virk A, Swift M, et al. Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing pre-procedural COVID-19 molecular screening. Clin Infect Dis. 2021;74:59&#x2013;65. doi: 10.1093/cid/ciab229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab229</ArticleId><ArticleId IdType="pmc">PMC7989519</ArticleId><ArticleId IdType="pubmed">33704435</ArticleId></ArticleIdList></Reference><Reference><Citation>Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA. 2021;325:2457&#x2013;65. doi: 10.1001/jama.2021.7152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.7152</ArticleId><ArticleId IdType="pmc">PMC8220476</ArticleId><ArticleId IdType="pubmed">33956048</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819&#x2013;29. doi: 10.1016/s0140-6736(21)00947-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00947-8</ArticleId><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397:1725&#x2013;35. doi: 10.1016/S0140-6736(21)00790-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00790-X</ArticleId><ArticleId IdType="pmc">PMC8064668</ArticleId><ArticleId IdType="pubmed">33901423</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ASV, Gribben C, Bishop J, Hanlon P, Caldwell D, Wood R, et al. Effect of vaccination on transmission of SARS-CoV-2. N Engl J Med. 2021;385:1718&#x2013;20. doi: 10.1056/nejmc2106757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmc2106757</ArticleId><ArticleId IdType="pmc">PMC8451182</ArticleId><ArticleId IdType="pubmed">34496200</ArticleId></ArticleIdList></Reference><Reference><Citation>Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone MA, Koycheva A, et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2021;S1473-3099(21):00648&#x2013;4. doi: 10.1016/s1473-3099(21)00648-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(21)00648-4</ArticleId><ArticleId IdType="pmc">PMC8554486</ArticleId><ArticleId IdType="pubmed">34756186</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9:129. doi: 10.1016/s2213-2600(21)00031-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2213-2600(21)00031-x</ArticleId><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re&#x2019;em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistics OfN  Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK &#x2013; 7 October 2021. . 2021. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/7october2021 Available from:</Citation></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. medRxiv. 2021 doi: 10.1101/2021.06.28.21259452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.28.21259452</ArticleId></ArticleIdList></Reference><Reference><Citation>Health F. A detailed study of patients with long-haul COVID. An analysis of private healthcare claims. . 2021. https://www.fairhealth.org/press-release/nineteen-percent-of-asymptomatic-covid-19-patients-develop-long-haul-covid Available from: [Updated 2021]</Citation></Reference><Reference><Citation>Huang Y, Pinto MD, Borelli JL, Mehrabadi MA, Abrihim H, Dutt N, et al. COVID symptoms, symptom clusters, and predictors for becoming a long-hauler: looking for clarity in the haze of the pandemic. medRxiv. 2021 doi: 10.1101/2021.03.03.21252086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.03.21252086</ArticleId><ArticleId IdType="pmc">PMC9510954</ArticleId><ArticleId IdType="pubmed">36154716</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemi&#x144;ska I, W&#x119;glarczyk K, Surmiak M, Kurowska-Baran D, Sanak M, Siedlar M, et al. Mild and asymptomatic COVID-19 convalescents present long-term endotype of immunosuppression associated with neutrophil subsets possessing regulatory functions. Front Immunol. 2021;12:748097. doi: 10.3389/fimmu.2021.748097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.748097</ArticleId><ArticleId IdType="pmc">PMC8511487</ArticleId><ArticleId IdType="pubmed">34659245</ArticleId></ArticleIdList></Reference><Reference><Citation>Doykov I, H&#xe4;llqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE. &#x2018;The long tail of Covid-19&#x2019; - the detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res. 2020;9:1349. doi: 10.12688/f1000research.27287.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.27287.1</ArticleId><ArticleId IdType="pmc">PMC7745182</ArticleId><ArticleId IdType="pubmed">33391730</ArticleId></ArticleIdList></Reference><Reference><Citation>Cyranoski D. Alarming COVID variants show vital role of genomic surveillance. Nature. 2021;589:337&#x2013;8. doi: 10.1038/d41586-021-00065-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-00065-4</ArticleId><ArticleId IdType="pubmed">33452508</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Tracking SARS-CoV-2 variants. . 2021. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ Available from: [Updated 2021]</Citation></Reference><Reference><Citation>Torjesen I. Covid-19: omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ (Clin Res Ed) 2021;375:n2943. doi: 10.1136/bmj.n2943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2943</ArticleId><ArticleId IdType="pubmed">34845008</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature. 2020;588:327&#x2013;30. doi: 10.1038/s41586-020-2772-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2772-0</ArticleId><ArticleId IdType="pmc">PMC7116727</ArticleId><ArticleId IdType="pubmed">32942285</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182:812&#x2013;27 e19. doi: 10.1016/j.cell.2020.06.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.043</ArticleId><ArticleId IdType="pmc">PMC7332439</ArticleId><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control.  Epidemiological update: omicron variant of concern (VOC) &#x2013; data as of 1 December 2021 (12.00) . 2021. https://www.ecdc.europa.eu/en/news-events/epidemiological-update-omicron-data-1-december-2021 Available from: [Updated 2021]</Citation></Reference><Reference><Citation>U.S. News  Botswana&#x2019;s health director says majority of omicron variant cases were asymptomatic. . 2021. https://www.usnews.com/news/world/articles/2021-12-01/botswanas-health-director-says-majority-of-omicron-variant-cases-were-asymptomatic Available from: [Updated 2021]</Citation></Reference><Reference><Citation>Firestone MJ, Lorentz AJ, Wang X, Como-Sabetti K, Vetter S, Smith K, et al. First identified cases of SARS-CoV-2 variant B.1.1.7 in Minnesota &#x2013; December 2020&#x2013;January 2021. MMWR Morb Mortal Wkly Rep. 2021;70:278&#x2013;9. doi: 10.15585/mmwr.mm7008e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7008e1</ArticleId><ArticleId IdType="pmc">PMC8344980</ArticleId><ArticleId IdType="pubmed">33630825</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England . Investigation of novel SARS-CoV-2 variant: variant of concern 202012/01. PHE Technical Briefing; 2020.</Citation></Reference><Reference><Citation>Maggi F, Novazzi F, Genoni A, Baj A, Spezia PG, Focosi D, et al. Imported SARS-CoV-2 variant P.1 in traveler returning from Brazil to Italy. Emerg Infect Dis. 2021;27:1249&#x2013;51. doi: 10.3201/eid2704.210183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2704.210183</ArticleId><ArticleId IdType="pmc">PMC8007292</ArticleId><ArticleId IdType="pubmed">33567246</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Biodefense Staff  Patients with alpha and beta COVID-19 variants less likely to be asymptomatic, despite no increase in viral load. . 2021. https://globalbiodefense.com/2021/06/23/patients-with-alpha-and-beta-covid-19-variants-less-likely-to-be-asymptomatic-despite-no-increase-in-viral-load/ Available from:</Citation></Reference><Reference><Citation>Adamoski D, de Oliveira JC, Bonatto AC, Wassem R, Nogueira MB, Raboni SM, et al. Large-scale screening of asymptomatic persons for SARS-CoV-2 variants of concern and gamma takeover, Brazil. Emerg Infect Dis. 2021;27:3124&#x2013;7. doi: 10.3201/eid2712.211326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2712.211326</ArticleId><ArticleId IdType="pmc">PMC8632178</ArticleId><ArticleId IdType="pubmed">34533453</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  WHO press conference on coronavirus disease (COVID-19) &#x2013; 12 July 2021. . 2021. https://www.who.int/multi-media/details/who-press-conference-on-coronavirus-disease-(covid-19)---12-july-2021 Available from:</Citation></Reference><Reference><Citation>Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa. medRxiv. 2021 doi: 10.1101/2021.12.21.21268116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.21.21268116</ArticleId><ArticleId IdType="pmc">PMC8769664</ArticleId><ArticleId IdType="pubmed">35065011</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz Sheikh SK, Woolhouse M, McMenamin J, Robertson C. . 2021. Severity of omicron variant of concern and vaccine effectiveness against symptomatic disease: national cohort with nested test negative design study in Scotland. Edinburgh: THE UNIVERSITY of EDINBURGH.</Citation></Reference><Reference><Citation>Garrett N, Tapley A, Andriesen J, Seocharan I, Fisher LH, Bunts L, et al. High rate of asymptomatic carriage associated with variant strain omicron. medRxiv. 2021 doi: 10.1101/2021.12.20.21268130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.20.21268130</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384:1885&#x2013;98. doi: 10.1056/NEJMoa2102214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2102214</ArticleId><ArticleId IdType="pmc">PMC7993410</ArticleId><ArticleId IdType="pubmed">33725432</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto S, Maeda K, Matsuda K, Tanaka A, Horii K, Okudera K, et al. COVID-19 breakthrough infection and post-vaccination neutralizing antibody among healthcare workers in a referral hospital in Tokyo: a case-control matching study. Clin Infect Dis. 2021:ciab1048. doi: 10.1093/cid/ciab1048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab1048</ArticleId><ArticleId IdType="pmc">PMC8755292</ArticleId><ArticleId IdType="pubmed">34950947</ArticleId></ArticleIdList></Reference><Reference><Citation>Han E, Tan MMJ, Turk E, Sridhar D, Leung GM, Shibuya K, et al. Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe. Lancet. 2020;396:1525&#x2013;34. doi: 10.1016/s0140-6736(20)32007-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)32007-9</ArticleId><ArticleId IdType="pmc">PMC7515628</ArticleId><ArticleId IdType="pubmed">32979936</ArticleId></ArticleIdList></Reference><Reference><Citation>Her M. How is COVID-19 affecting South Korea? What is our current strategy? Disaster Med Public Health Prep. 2020;14:684&#x2013;6. doi: 10.1017/dmp.2020.69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/dmp.2020.69</ArticleId><ArticleId IdType="pmc">PMC7160162</ArticleId><ArticleId IdType="pubmed">32241325</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong JEL, Leo YS, Tan CC. COVID-19 in Singapore-current experience: critical global issues that require attention and action. JAMA. 2020;323:1243&#x2013;4. doi: 10.1001/jama.2020.2467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2467</ArticleId><ArticleId IdType="pubmed">32077901</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong C.  Patients who are well but still testing positive for COVID-19 to be moved to community isolation facility to preserve hospital capacity. 2020. https://www.straitstimes.com/singapore/patients-who-are-well-but-still-testing-positive-for-covid-19-to-be-moved-to-community The Straits Times.</Citation></Reference><Reference><Citation>NRHCC Media  COVID-19 sentinel community testing undertaken in Auckland. . 2020. https://www.countiesmanukau.health.nz/news/covid-19-sentinel-community-testing-undertaken-in-auckland/ Available from:</Citation></Reference><Reference><Citation>Gai R, Tobe M. Managing healthcare delivery system to fight the COVID-19 epidemic: experience in Japan. Global Health Res Pol. 2020;5:23. doi: 10.1186/s41256-020-00149-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41256-020-00149-0</ArticleId><ArticleId IdType="pmc">PMC7220603</ArticleId><ArticleId IdType="pubmed">32432167</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J-M, Takenaka K. As Japan reopens, coronavirus testing slowed by bureaucracy and staff shortages. . 2020. https://www.reuters.com/article/us-health-coronavirus-japantesting/as-japan-reopens-coronavirus-testing-slowed-by-bureaucracyand-staff-shortages-idUSKBN23406H Available from:</Citation></Reference><Reference><Citation>Folkehelseinstituttet  Un&#xf8;dvendig &#xe5; teste store grupper av friske ved lite koronasmitte. . 2020. https://www.fhi.no/nyheter/2020/unodvendig-a-teste-store-grupper-av-friske-ved-lite-koronasmitte Available from:</Citation></Reference><Reference><Citation>Vigsn&#xe6;s MK. Nye testkriterier: slik tester du deg for korona n&#xe5;. . 2020. https://www.nrk.no/norge/nye-testkriterier_-slik-tester-du-deg-for-korona-na-1.15119739 Available from:</Citation></Reference><Reference><Citation>Chen H, Shi L, Zhang Y, Wang X, Jiao J, Yang M, et al. Response to the COVID-19 pandemic: comparison of strategies in six countries. Front Public Health. 2021;9:708496. doi: 10.3389/fpubh.2021.708496.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.708496</ArticleId><ArticleId IdType="pmc">PMC8515016</ArticleId><ArticleId IdType="pubmed">34660510</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584:257&#x2013;61. doi: 10.1038/s41586-020-2405-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2405-7</ArticleId><ArticleId IdType="pubmed">32512579</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira JF, Jorge DCP, Veiga RV, Rodrigues MS, Torquato MF, da Silva NB, et al. Mathematical modeling of COVID-19 in 14.8 million individuals in Bahia, Brazil. Nat Commun. 2021;12:333. doi: 10.1038/s41467-020-19798-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19798-3</ArticleId><ArticleId IdType="pmc">PMC7803757</ArticleId><ArticleId IdType="pubmed">33436608</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514&#x2013;23. doi: 10.1016/s0140-6736(20)30154-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30154-9</ArticleId><ArticleId IdType="pmc">PMC7159286</ArticleId><ArticleId IdType="pubmed">31986261</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller M, Derlet PM, Mudry C, Aeppli G. Testing of asymptomatic individuals for fast feedback-control of COVID-19 pandemics. Phys Biol. 2020 doi: 10.1088/1478-3975/aba6d0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1478-3975/aba6d0</ArticleId><ArticleId IdType="pubmed">33048841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>